GoldenGolden
Advanced Search
Roche

Roche

A biotechnology company with a focus on developing pharmaceuticals and diagnostics. It was founded in 1896 and is located in Basel, Switzerland.

Roche is a Switzerland-based biotechnology company that develops therapeutics and diagnostics for oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company has more than 900,000 employees throughout 100 countries. It states that it is the world's largest biopharmaceutical company and the lead supplier of in vitro diagnostics.

Product

The company has research and development in progress for pharmaceuticals and diagnostics for haemophilia, women's health, inflammatory bowel disease, and neuroscience. The facilities for this research are located in the United States, Austria, Germany, Poland, Switzerland, South Africa, and China.Roche conducts clinical trials and once they are successfully completed the pharmaceuticals are produced in an experimental lab to ensure scalability. The company has manufacturing facilities for its therapeutics, including facilities for its biologics.

Roche offers more than 40 pharmaceuticals, including Hemlibra, Micera, and Tamiflu.

Timeline

December 11, 2020
Roche launches high-throughput COVID-19 antigen test in Europe.

November 16, 2020
Lead Pharma enters into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune-mediated diseases.

December 2019
Roche completes its acquisition of Spark Therapeutics for $4.3 billion.
March 2009
Genentech and Roche merge.
1968
Roche enters the diagnostics market.
1896
Roche is founded by Fritz Hoffmann-La Roche in Switzerland.

Funding rounds

Acquisitions

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

F. Hoffmann-La Roche Ltd

Web

October 13, 2020

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting

F. Hoffmann-La Roche Ltd

Web

November 5, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
October 13, 2021
FierceBiotech
Aum Biosciences is moving on to oncology turf targeted by companies including Bayer and Roche, securing $27 million to take inhibitors of MNK and TRK into midphase clinical trials.
Annalee Armstrong
October 12, 2021
FierceBiotech
Roche's Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene's gene therapy for epilepsy, which has a specific focus on drug-resistant forms of the condition.
Nick Paul
October 4, 2021
FierceBiotech
The race to use bispecifics to treat blood cancers is heating up, with Johnson & Johnson paying $100 million upfront to challenge Regeneron and Roche in a field that looks set to be highly competitive.
Kyle LaHucik
September 27, 2021
FierceBiotech
Roche's Genentech will start communicating personalized information to patients, clinical trial participants and providers via a digital chatbot. The goal is to be able to provide information on a smartphone to more people.
Andrea Park
September 14, 2021
FierceBiotech
After spending more than a century honing its pharmacological approach to managing disease, Roche is branching out. The Big Pharma has partnered with digital health software developer Temedica to help multiple sclerosis patients manage their condition using a smartphone app.
Conor Hale
September 9, 2021
FierceBiotech
The Berlin-based diagnostics company, which has worked with Roche for more than two decades, specializes in rapid test development in the face of infectious disease outbreaks, to respond to emerging threats within days.
Ben Adams
September 9, 2021
FierceBiotech
Cancer trials typically have to be done within a hospital or community healthcare setting, but Science 37 and Roche's genomics unit Foundation Medicine are teaming up to move some of this to an at-home setting.
Kyle LaHucik
September 7, 2021
FierceBiotech
Roche is making a big play in off-the-shelf cell therapies, putting up a potential $3 billion in biobucks for Adaptimmune to develop up to five cancer targets. Roche's Genentech unit will dish out $150 million upfront to Adaptimmune to develop and commercialize allogeneic cell therapies for up to five shared cancer targets, the companies said Tuesday.
Ben Adams
September 7, 2021
FierceBiotech
Roche, like so many others in the field, has seen major setbacks in trying to hunt new drugs for Huntington's disease, but it's brushing off a recent flop and signing up with a new partner in the hopes of trying again.
Amirah Al Idrus
August 24, 2021
FierceBiotech
Roche may market the first FDA-approved in vivo gene therapy, but the company isn't resting on its laurels. The Swiss pharma is teaming up with Shape Therapeutics on next-generation gene therapies for Alzheimer's, Parkinson's and rare diseases in a deal that could exceed $3 billion.
August 4, 2021
WebWire
, , , , • Application is being reviewed under the US FDA's Real-Time Oncology Review pilot programme , , • Based on results of the Phase III IMpower010 study, presented at ASCO, that showed adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive early-stage lung cancer, compared with best supportive care , , • Tecentriq is the first and only cancer immunotherapy to demonstrate positive Phase III results in the adjuvant lung cancer setting , , , , , , Roche...
Kyle LaHucik
August 3, 2021
FierceBiotech
Patients receiving Lumosa Therapeutics' stroke drug were not at an increased risk of experiencing a serious brain hemorrhage, meeting the main goal of a midstage study and setting up the small biotech to join a billion-dollar market owned by Roche. The main goal of the small phase 2a study was to determine the percentage of patients with acute ischemic stroke who experienced a serious brain bleed called symptomatic intracranial hemorrhage after treatment.
Kyle LaHucik
July 29, 2021
FierceBiotech
Bayer named Roche oncology veteran Dominik Ruettinger, M.D., Ph.D., as head of research and early development for oncology. Bayer also made moves with subsidiary BlueRock Therapeutics promoting chief scientific officer Seth Ettenberg, Ph.D., to the role of CEO. And ex-Kiadis Chief Business Officer Ray Barlow became SynOx Therapeutics CEO.
Nick Paul
July 26, 2021
FierceBiotech
Bayer has appointed Dominik Ruettinger as its head of research and early development for oncology. Ruettinger is set to join the German conglomerate from Roche, following in the footsteps of Bayer's head of R&D Christian Rommel.
Nick Paul
July 22, 2021
FierceBiotech
Roche is talking to the FDA about its Alzheimer's disease drug candidate gantenerumab. CEO Severin Schwan declined to speculate on the outcome of the talks amid reports that it will join Eli Lilly in filing for accelerated approval in Alzheimer's.
Annalee Armstrong
July 21, 2021
FierceBiotech
As U.S. officials practically beg the unvaccinated to roll up their sleeves to gain protection from COVID-19, a new report is calling on pharmaceutical companies to be more transparent with their clinical trials and data sharing among peers to build trust in the medical system. A group of Yale bioethicists has found that the largest pharmaceutical companies are better at clinical trial transparency and sharing data amongst their peers and smaller companies could be doing more to catch up.
Brandon May
July 7, 2021
BioSpace
The WHO is calling for manufacturers to cut prices and increase the availability of supplies to low- and middle-income nations to parts of the world where COVID-19 continues to surge.
Nick Paul
July 2, 2021
FierceBiotech
Peter Braun is leaving Nordic Nanovector three months after joining the company as CEO. Nordic Nanovector attributed Braun's departure to "personal reasons" and named its chief financial officer to the top job on an interim basis.
Kyle LaHucik
July 1, 2021
FierceBiotech
The Swiss Big Pharma is looking at a "new prioritisation" and will likely make the cuts in its clinical development workforce, a Roche spokesperson confirmed.
July 1, 2021
mint
'We've made the difficult decision to reduce our workforce in PD by around 5-7% by the end of the year, Roche CMO Levi Garraway said. 'And that equates to somewhere between 300 to 400 roles that will be impacted globally'
SHOW MORE

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.